173 related articles for article (PubMed ID: 37928274)
21. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
22. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Huang K; Chen J; Yang MS; Tang YJ; Pan F
Cancer Biomark; 2017; 18(3):231-239. PubMed ID: 28085008
[TBL] [Abstract][Full Text] [Related]
24. Targeting glucose metabolism in chondrosarcoma cells enhances the sensitivity to doxorubicin through the inhibition of lactate dehydrogenase-A.
Hua G; Liu Y; Li X; Xu P; Luo Y
Oncol Rep; 2014 Jun; 31(6):2727-34. PubMed ID: 24789077
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin upregulates glutamine transport in human intestinal epithelial cells: the protective mechanism of glutamine on intestinal mucosa after chemotherapy.
Nose S; Wasa M; Tazuke Y; Owari M; Fukuzawa M
JPEN J Parenter Enteral Nutr; 2010; 34(5):530-7. PubMed ID: 20852181
[TBL] [Abstract][Full Text] [Related]
26. Altered glutamine metabolism in platinum resistant ovarian cancer.
Hudson CD; Savadelis A; Nagaraj AB; Joseph P; Avril S; DiFeo A; Avril N
Oncotarget; 2016 Jul; 7(27):41637-41649. PubMed ID: 27191653
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
Eckstein N; Servan K; Girard L; Cai D; von Jonquieres G; Jaehde U; Kassack MU; Gazdar AF; Minna JD; Royer HD
J Biol Chem; 2008 Jan; 283(2):739-50. PubMed ID: 17942395
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer.
Ma H; Wu J; Zhou M; Wu J; Wu Z; Lin L; Huang N; Liao W; Sun L
Integr Cancer Ther; 2021; 20():15347354211045349. PubMed ID: 34590499
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.
Ge J; Wang B; Zhao S; Xu J
Bioengineered; 2022 Mar; 13(3):7670-7682. PubMed ID: 35313796
[TBL] [Abstract][Full Text] [Related]
30. ASCT2-mediated glutamine uptake promotes Th1 differentiation via ROS-EGR1-PAC1 pathway in oral lichen planus.
Li W; Ling Z; Wang J; Su Z; Lu J; Yang X; Cheng B; Tao X
Biochem Pharmacol; 2023 Oct; 216():115767. PubMed ID: 37634599
[TBL] [Abstract][Full Text] [Related]
31. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
32. Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3
Zhou Q; Lin W; Wang C; Sun F; Ju S; Chen Q; Wang Y; Chen Y; Li H; Wang L; Hu Z; Jin H; Wang X; Sun Y
Nat Commun; 2022 May; 13(1):3034. PubMed ID: 35641493
[TBL] [Abstract][Full Text] [Related]
33. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
[TBL] [Abstract][Full Text] [Related]
34. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.
Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D
J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chen C; Zhou H; Xu L; Xu D; Wang Y; Zhang Y; Liu X; Liu Z; Ma D; Ma Q; Chen Y
Apoptosis; 2010 Jul; 15(7):805-13. PubMed ID: 20349137
[TBL] [Abstract][Full Text] [Related]
36. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
37. miR-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell through Targeting the Glutaminase [GLS]-Mediated Glutamine Metabolism.
Zhou X; Wei P; Wang X; Zhang J; Shi Y
Curr Mol Med; 2023; 23(2):177-184. PubMed ID: 34607540
[TBL] [Abstract][Full Text] [Related]
38. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.
Polet F; Martherus R; Corbet C; Pinto A; Feron O
Oncotarget; 2016 Jul; 7(29):46371-46383. PubMed ID: 27344174
[TBL] [Abstract][Full Text] [Related]
40. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
